FR14C0010I2 - USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE ACID FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Google Patents
USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE ACID FOR THE TREATMENT OF MULTIPLE SCLEROSISInfo
- Publication number
- FR14C0010I2 FR14C0010I2 FR14C0010C FR14C0010C FR14C0010I2 FR 14C0010 I2 FR14C0010 I2 FR 14C0010I2 FR 14C0010 C FR14C0010 C FR 14C0010C FR 14C0010 C FR14C0010 C FR 14C0010C FR 14C0010 I2 FR14C0010 I2 FR 14C0010I2
- Authority
- FR
- France
- Prior art keywords
- enoic
- trifluoromethylphenyl
- cyano
- hydroxy
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28168501P | 2001-04-05 | 2001-04-05 | |
GBGB0123571.2A GB0123571D0 (en) | 2001-04-05 | 2001-10-02 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
PCT/US2002/010773 WO2002080897A1 (en) | 2001-04-05 | 2002-04-04 | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
FR14C0010I1 FR14C0010I1 (en) | 2014-03-14 |
FR14C0010I2 true FR14C0010I2 (en) | 2014-11-21 |
Family
ID=26246599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR14C0010C Active FR14C0010I2 (en) | 2001-04-05 | 2014-02-05 | USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE ACID FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP1381356B1 (en) |
AR (1) | AR033459A1 (en) |
AT (1) | ATE396719T1 (en) |
CA (1) | CA2443285C (en) |
CY (1) | CY2014004I2 (en) |
DE (1) | DE60226855D1 (en) |
DK (1) | DK1381356T3 (en) |
ES (1) | ES2305287T3 (en) |
FR (1) | FR14C0010I2 (en) |
LU (1) | LU92366I2 (en) |
PA (1) | PA8542901A1 (en) |
PT (1) | PT1381356E (en) |
SI (1) | SI1381356T1 (en) |
UY (1) | UY27244A1 (en) |
WO (1) | WO2002080897A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003293500A1 (en) | 2002-12-12 | 2004-07-09 | Agennix Incorporated | Lactoferrin in the reduction of pain |
AU2005295511A1 (en) * | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
AU2005318163B2 (en) | 2004-12-21 | 2011-12-01 | Merck Serono Sa | Sulfonyl amino cyclic derivatives and use thereof |
UA86862C2 (en) | 2005-01-31 | 2009-05-25 | Лаборатуар Сероно С.А. | N-hydroxyamide derivatives and use thereof |
WO2007025991A2 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
ES2319596B1 (en) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF THE AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS. |
EP2100881A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Pyrimidyl- or pyridinylaminobenzoic acid derivatives |
UY31272A1 (en) | 2007-08-10 | 2009-01-30 | Almirall Lab | NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID |
EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
EP2277515A1 (en) * | 2009-07-10 | 2011-01-26 | Sanofi-Aventis | Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
SI2477611T1 (en) * | 2009-09-18 | 2017-07-31 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
WO2012109329A2 (en) | 2011-02-08 | 2012-08-16 | Children's Medical Center Corporation | Methods for treatment of melanoma |
EP2762135A1 (en) * | 2013-02-04 | 2014-08-06 | Sanofi | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
US20180147148A1 (en) | 2015-05-23 | 2018-05-31 | Ftf Pharma Private Limited | Pharmaceutical composition of teriflunomide |
JOP20190207A1 (en) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | Pharmaceutical combination comprising ponesimod |
GR1010137B (en) | 2020-12-15 | 2021-12-07 | Φαρματεν Α.Β.Ε.Ε., | Immediate release solid dosage form comprising teriiflunomide and method of prepeartion thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES448386A1 (en) | 1975-06-05 | 1978-04-16 | Hoechst Ag | 5-Methyl-isoxazole-4-carboxylic acid anilides |
DE2854439A1 (en) | 1978-12-16 | 1980-07-03 | Hoechst Ag | AN ISOXAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AGENT AND USE THEREOF |
DE3534440A1 (en) | 1985-09-27 | 1987-04-02 | Hoechst Ag | DRUGS AGAINST CHRONIC GRAFT VERSUS HOST DISEASES AND AUTO AUTO DISEASES, IN PARTICULAR SYSTEMIC LUPUS ERYTHEMATODES |
US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
TW314467B (en) | 1993-03-31 | 1997-09-01 | Hoechst Ag | |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
DE19547648A1 (en) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Preparation containing high density lipoproteins and crotonic acid amide derivatives |
-
2002
- 2002-04-04 EP EP02763962A patent/EP1381356B1/en not_active Expired - Lifetime
- 2002-04-04 DK DK02763962T patent/DK1381356T3/en active
- 2002-04-04 DE DE60226855T patent/DE60226855D1/en not_active Expired - Lifetime
- 2002-04-04 SI SI200230727T patent/SI1381356T1/en unknown
- 2002-04-04 EP EP08004647A patent/EP1935416A3/en not_active Ceased
- 2002-04-04 PT PT02763962T patent/PT1381356E/en unknown
- 2002-04-04 AR ARP020101245A patent/AR033459A1/en not_active Application Discontinuation
- 2002-04-04 ES ES02763962T patent/ES2305287T3/en not_active Expired - Lifetime
- 2002-04-04 WO PCT/US2002/010773 patent/WO2002080897A1/en not_active Application Discontinuation
- 2002-04-04 CA CA002443285A patent/CA2443285C/en not_active Expired - Fee Related
- 2002-04-04 AT AT02763962T patent/ATE396719T1/en active
- 2002-04-05 UY UY27244A patent/UY27244A1/en unknown
- 2002-04-05 PA PA20028542901A patent/PA8542901A1/en unknown
-
2014
- 2014-01-23 CY CY2014004C patent/CY2014004I2/en unknown
- 2014-01-29 LU LU92366C patent/LU92366I2/en unknown
- 2014-02-05 FR FR14C0010C patent/FR14C0010I2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK1381356T3 (en) | 2008-09-22 |
ES2305287T3 (en) | 2008-11-01 |
AR033459A1 (en) | 2003-12-17 |
ATE396719T1 (en) | 2008-06-15 |
CY2014004I1 (en) | 2015-12-09 |
EP1935416A3 (en) | 2008-10-22 |
DE60226855D1 (en) | 2008-07-10 |
CA2443285C (en) | 2007-08-21 |
EP1381356B1 (en) | 2008-05-28 |
LU92366I2 (en) | 2014-03-31 |
UY27244A1 (en) | 2002-07-31 |
EP1381356A1 (en) | 2004-01-21 |
SI1381356T1 (en) | 2008-12-31 |
PA8542901A1 (en) | 2003-11-12 |
CY2014004I2 (en) | 2015-12-09 |
FR14C0010I1 (en) | 2014-03-14 |
WO2002080897A1 (en) | 2002-10-17 |
CA2443285A1 (en) | 2002-10-17 |
PT1381356E (en) | 2008-07-24 |
EP1935416A2 (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR14C0010I2 (en) | USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE ACID FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
FR2843295B1 (en) | INSTRUMENT FOR TREATING FRACTURE OF BRAIN DAMAGE | |
FR07C0046I2 (en) | BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | |
FR2846870B1 (en) | OSTEOSYNTHESIS EQUIPMENT FOR THE TREATMENT OF A "LONG" CUBITUS | |
ITMI20022234A1 (en) | APPARATUS AND PROCEDURE FOR THE PERFORMANCE OF CODING | |
MA26950A1 (en) | NEW RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | |
FR2829142B1 (en) | FILMOGENEOUS COMPOSITION OF HETEROXYLANE FOR THE MANUFACTURE OF CAPSULES THUS OBTAINED | |
ITMI20012052A0 (en) | PROCEDURE FOR THE CAPITATION AND REMOVAL OF VOLATILE DUST | |
GB0123571D0 (en) | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis | |
MA26289A1 (en) | LOW CONCENTRATION OF PEROXIDE FOR THE TREATMENT OR PREVENTION OF VAGINAL INFECTIONS | |
MA24332A1 (en) | USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SKIN INFECTIONS | |
PT1377544E (en) | Purification of 2-nitro-4-methylsulphonylbenzoic acid | |
FR2835851B1 (en) | COMPOSITION FOR THE TREATMENT OF MAGNESIUM ALLOYS | |
MA26117A1 (en) | NEW COMPOUND FOR THE TREATMENT OF IMPOTENCE | |
FR2837101B1 (en) | USE OF 6- [1-ADAMANTYL) -4-METHOXYPHENYL] -2- NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | |
FR2833198B1 (en) | DEVICE FOR THE TREATMENT OF MECHANICAL SURFACES OF WORKPIECES | |
FR2810547B1 (en) | USE OF C2-C10 ACIDS FOR THE PREVENTION OF NEGATIVE GRAM BACTERIA INFECTIONS | |
FR2800614B1 (en) | COMPOSITION FOR THE TREATMENT OF RESPIRATORY INFECTIONS | |
MA25852A1 (en) | METHOD FOR THE TREATMENT OF INFLAMMATION. | |
NO20025964L (en) | New interferon for the treatment of multiple sclerosis | |
FR2811998B1 (en) | USE OF HETEROXYLANES FOR THE PREPARATION OF FILM-FORMING COMPOSITIONS | |
FR2820967B1 (en) | EXTERNAL FIXER FOR IMMOBILIZATION OF FRACTURED BONE PARTS | |
MA26908A1 (en) | S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF PSYCHIATRIC AND EYE DISORDERS | |
MA27530A1 (en) | USE OF LEVOCETIRIZINE FOR THE TREATMENT OF PERSISTENT ALLERGIC RHINITIS. | |
FI20011560A0 (en) | Compounds Useful for the Treatment or Prevention of Alpha-2B Adrenoceptor Mediated Disease |